Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume control Clear all
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

NCT03779841
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AGN-151607, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients

NCT00747045
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, Acute Lung Injury
Interventions
Ventilation Strategy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 24, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes

NCT02131766
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
DiAs, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 24, 2026, 5:02 PM EDT
Withdrawn Not applicable Interventional

Colonic Irrigation for Colonoscopy Preparation

NCT02647229
View directory record Official record
Conditions
Colonoscopy
Interventions
Isosmotic bowel cleansing preparation, Colonic Hyrdrotherapy
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 24, 2026, 5:02 PM EDT
Terminated Phase 3 Interventional Results available

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

NCT06524739
View directory record Official record
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome
Interventions
IgPro20, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 24, 2026, 5:02 PM EDT
Active, not recruiting Not applicable Interventional

Concordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS)

NCT07178470
View directory record Official record
Conditions
Fluid Overload, POCUS, Lung Ultrasound, Volume Status
Interventions
point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), Modified Medical Research Council (mMRC) Dyspnea scale, Physical Exam
Device · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 5:02 PM EDT
Recruiting Phase 4 Interventional

Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

NCT07419854
View directory record Official record
Conditions
Volume Loss (Soft Tissue Ptosis or Atrophy )
Interventions
Hyperdiluted Calcium Hydroxylapatite, Calcium hydroxylapatite, Calcium hydroxylapatite with integral lidocaine
Device
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01275066
View directory record Official record
Conditions
MPS IV A
Interventions
BMN 110 Weekly, Placebo, BMN 110 Every Other Week
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis

NCT02677883
View directory record Official record
Conditions
Pleural Effusion
Interventions
Manometry-guided thoracentesis, Symptom-guided thoracentesis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Inhalation Treatment for Dyspnea - Patients

NCT02524054
View directory record Official record
Conditions
Dyspnea
Interventions
Furosemide, Aerosolized saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

NCT01746784
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N6022, Normal saline
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 24, 2026, 5:02 PM EDT
Terminated Not applicable Interventional Results available

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

NCT04025021
View directory record Official record
Conditions
Human Milk, Neonate, Breast Milk
Interventions
Targeted Fortification, The Miris Human Milk Analyzer
Dietary Supplement · Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
Up to 6 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 24, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 24, 2026, 5:02 PM EDT
Withdrawn Early Phase 1 Interventional

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation

NCT03330704
View directory record Official record
Conditions
Cerebral Edema, Saline Solution, Hypertonic
Interventions
3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

NCT05166889
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
36
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 24, 2026, 5:02 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Postoperative Pain Control & Relief in Neonates

NCT03677830
View directory record Official record
Conditions
Pain, Postoperative, Premature Infant, Opioid Use
Interventions
Acetaminophen, Saline
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 1 Month
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 24, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

NCT00495521
View directory record Official record
Conditions
Crohn's Disease
Interventions
4-Aminosalicylic acid extended release granules
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
2 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 24, 2026, 5:02 PM EDT